It did achieve the primary endpoint:
"Viraleze™ achieved a statistically significantly lower level of SARS-CoV-2 viral load3 in the nose over the 7-day treatment period, which was the primary endpoint of the study, than a placebo nasal spray in the cohort of participants aged 45 years and over (N=118, p=0.017)."
Also worth noting is this comment:
"Of note, treatment compliance and vaccination rates were lowest in participants aged under 40."
It has clinical benefit, especially for older cohorts (aged care and hospitals spring to mind, as well as travel) and importantly it has little or no side effects, so it has a good risk/reward profile.
The target market would be over 40s anyway IMO. My kids hate taking the stuff, and they are adults now, so no surprise they had trouble with compliance in younger participants!
They just need to get the approvals, deals and dollars through the door.
It did achieve the primary endpoint: "Viraleze™ achieved a...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
-0.005(4.00%) |
Mkt cap ! $49.44M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 12.0¢ | $34.86K | 289.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 263226 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 57773 | 3 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.5¢ |
Change
-0.005 ( 4.17 %) |
||||
| Open | High | Low | Volume | ||
| 12.0¢ | 12.5¢ | 12.0¢ | 6229 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| SPL (ASX) Chart |